Publications by authors named "I G Schmidt-Wolf"
Background: Cytokine-induced killer (CIK) cell therapy has proven successful in clinical trials regarding glioblastoma. Equally important are the hints suggesting peroxisome proliferator-activated receptors (PPARs) ligands being co-expressed in the central nervous system (CNS). This provides a rationale about investigating the possible synergistic effect of CIK cells and PPARs.
View Article and Find Full Text PDFColorectal cancer (CRC) is one of the most common types of cancer with high incidence and mortality. Endoplasmic reticulum oxidoreductase 1 alpha (ERO1L) is overexpressed in CRC. This study aims to explore the role of ERO1L in CRC progression and evaluate the anti-tumor efficacy of the combination treatment of ERO1L inhibition with endoplasmic reticulum (ER) stress-inducing therapies.
View Article and Find Full Text PDFArticle Synopsis
- The text discusses adoptive cellular immunotherapy (ACT), a treatment that enhances the immune system's ability to recognize and attack tumor cells by using the patient's own immune cells.
- It highlights the advancements in ACT, particularly through chimeric antigen receptor (CAR) therapies, including CAR-T cells, CAR-NK, CAR-macrophages, CAR-γδT, and CAR-NKT, which have improved treatment outcomes for cancers like multiple myeloma (MM).
- Additionally, the text examines the potential of cytokine-induced killer (CIK) therapy, reviews significant research findings, and addresses challenges like cytokine release syndrome (CRS) and neurotoxicity that hinder the overall success of these therapies in cancer treatment
Aim: We focused on the FOXN3 gene and selected its antisense transcripts (FOXN3-AS1) to investigate its potential involvement in acute myeloid leukemia (AML).
Background: Several integrated multi-omics datasets have expanded the horizons of the cancer landscape. With the emergence of new high-throughput technologies, a large number of non-coding RNAs have been confirmed to be involved in the pathogenesis of different types of hematological malignancies.